

Ixazomib (NINLARO)

Criteria for Use

August 2024

VA Pharmacy Benefits Management Services, Medical Advisory Panel, and VISN Pharmacist Executives

Exclusion Criteria

If the answer to ANY item below is met, then the patient should NOT receive ixazomib.

- Use of ixazomib combination is for patient with newly diagnosed multiple myeloma
- Use of ixazomib combination is as maintenance myeloma therapy
- Patient is not a candidate for lenalidomide or dexamethasone therapy
- Absolute neutrophil count (ANC) less than 1000/mm³ unless due to marrow involvement or associated with Duffy-null associated neutrophil count
- Platelet count less than 75,000/mm³ unless due to marrow involvement
- Unmanageable drug-drug interaction
- Pregnancy
- Lactating

Inclusion Criteria

The answers to ALL of the following must be fulfilled in order to meet criteria.

- Care is provided by a VA/VA Community Care hematology or oncology provider
- Goals of care and role of Palliative Care consult have been discussed and documented
- Diagnosis of multiple myeloma with documented relapsed or progressive disease
- Received at least one prior therapy (that did not include ixazomib)
- Assess need for antiviral prophylaxis to reduce risk of herpes zoster reactivation

Additional Inclusion Criteria

- For patients who can become pregnant: Pregnancy must be excluded prior to receiving ixazomib
- For patients who can become pregnant: Counseling provided on potential risks vs benefits of treatment and the use of effective contraception during therapy and for at least 90 days following treatment
- For patients with partners who can become pregnant: Counseling provided on potential risks vs benefits of treatment and the use of effective contraception during therapy and for at least 90 days following treatment

Prepared 12/2016; Updated 8/2024

Contact: Berni Heron, Pharm.D., BCOP - VHA Pharmacy Benefits Management Services
